TaiGen Biopharmaceuticals Holdings Limited

As of June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited carries a market capitalization of 6.13B, placing it among publicly traded companies globally. Its enterprise value stands at 5.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TaiGen Biopharmaceuticals Holdings Limited's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited has 711.83M shares outstanding.

As of June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited trades at a trailing price-to-earnings ratio of 39.37. The price-to-sales ratio is 23.81, and the price-to-book ratio stands at 6.00.

As of June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited trades at an EV/EBITDA multiple of 54.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 20.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 61.08 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. TaiGen Biopharmaceuticals Holdings Limited trades at an EV/FCF ratio of 157.27, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 5.23B versus a market cap of 6.13B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited maintains a current ratio of 31.84, meaning it holds 31.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.12, indicating moderate leverage, while an interest coverage ratio of 108.06 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited posted a return on equity (ROE) of 15.55, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.61 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.43, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.91, useful for judging operating efficiency across full business cycles. The company generates approximately 7.07M in revenue per employee across its workforce of 36.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.28 indicates how many times TaiGen Biopharmaceuticals Holdings Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited recorded 11.63M in income tax expense. That works out to an effective tax rate of 6.92, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 168.00M, leaving 155.12M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, TaiGen Biopharmaceuticals Holdings Limited's stock has gained approximately 8.32% over the past 52 weeks. The 50-day moving average sits at 8.89, while the 200-day moving average is 10.24.

Over the twelve months ended June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited generated 256.46M in revenue and converted that into 155.12M in net income, yielding earnings per share of 0.22. EBITDA reached 96.71M, while operating income came in at 82.67M.

As of June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited holds 915.27M in cash and equivalents against 11.43M in total debt, resulting in a net debt position of -155.11M. Total book value stands at 1.02B, with working capital of 971.00M providing operational flexibility.

TaiGen Biopharmaceuticals Holdings Limited produced 53.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -21.09M in capital expenditures, free cash flow totaled 32.39M - equivalent to 0.05 per share.

Over the twelve months ended June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited posted a gross margin of 93.69, reflecting its pricing power and cost economics. The operating margin of 32.24 and net profit margin of 60.49 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.53, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to TaiGen Biopharmaceuticals Holdings Limited shareholders.

TaiGen Biopharmaceuticals Holdings Limited's most recent stock split took place on January 7, 2016.

As of June 30, 2026, TaiGen Biopharmaceuticals Holdings Limited has an Altman Z-Score of 99.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.